{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:57:57Z","timestamp":1792511877495,"version":"4.5.0"},"reference-count":252,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008305","name":"Western New England University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pharmthera.2023.108366","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:20:55Z","timestamp":1677277255000},"page":"108366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Ifosfamide - History, efficacy, toxicity and encephalopathy"],"prefix":"10.1016","volume":"243","author":[{"given":"Jeffrey R.","family":"Idle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diren","family":"Beyo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108366_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155220971843","article-title":"Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?","volume":"27","author":"Abahssain","year":"2021","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0090-9556(25)08471-5","article-title":"Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue","volume":"24","author":"Aeschlimann","year":"1996","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0015","first-page":"883","article-title":"Comparative pharmacokinetics of oral and intravenous ifosfamide\/mesna\/methylene blue therapy","volume":"26","author":"Aeschlimann","year":"1998","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0020","first-page":"2519","article-title":"Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide","volume":"32","author":"Alarcon","year":"1972","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0025","first-page":"1097","article-title":"Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878))","volume":"59","author":"Albo","year":"1975","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.2042-7158.1972.tb09065.x","article-title":"Activation of the antineoplastic drug isophosphamide by rat liver microsomes","volume":"24","author":"Allen","year":"1972","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0035","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/jps.2600611232","article-title":"Effect of microsomal activation on interaction between isophosphamide and DNA","volume":"61","author":"Allen","year":"1972","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0040","first-page":"721","article-title":"Gas chromatographic method for the determination of plasma isophosphamide (NSC-109724)","volume":"56","author":"Allen","year":"1972","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0045","first-page":"603","article-title":"In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes","volume":"56","author":"Allen","year":"1972","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0050","first-page":"451","article-title":"Studies on the human pharmacokinetics of isophosphamide (NSC-109724)","volume":"60","author":"Allen","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0277-5379(83)90417-0","article-title":"Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer","volume":"19","author":"Araujo","year":"1983","journal-title":"European Journal of Cancer & Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0060","first-page":"15","article-title":"Comparison of ifosfamid with cyclophosphamide in the therapy of rat DS carcinosarcoma","volume":"38","author":"von Ardenne","year":"1971","journal-title":"Archiv f\u00fcr Geschwulstforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0065","first-page":"2113","article-title":"Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys","volume":"48","author":"Arndt","year":"1988","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ange.19580701705","article-title":"Synthese und Abbau cytostatisch wirksamer cyclischer N-Phosphamidester des Bis-(\u03b2-chlor\u00e4thyl)-amins","volume":"70","author":"Arnold","year":"1958","journal-title":"Angewandte Chemie"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/181931a0","article-title":"Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat","volume":"181","author":"Arnold","year":"1958","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0080","first-page":"735","article-title":"Degradation of nitrogen mustard N-oxide in aqueous solutions","volume":"7","author":"Arnold","year":"1957","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0085","first-page":"997","article-title":"Use of cyclophosphamide in advanced malignancies","volume":"83","author":"Aronovitch","year":"1960","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0003-2697(86)90621-4","article-title":"Monitoring exposure to acrylamide by the determination of S-(2-carboxyethyl)cysteine in hydrolyzed hemoglobin by gas chromatography-mass spectrometry","volume":"157","author":"Bailey","year":"1986","journal-title":"Analytical Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0095","first-page":"2755","article-title":"Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile","volume":"30","author":"Banh","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911391","article-title":"Mitochondrial DNA repair in neurodegenerative diseases and ageing","volume":"23","author":"Bazzani","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fncel.2020.00051","article-title":"Ischemia-triggered glutamate excitotoxicity from the perspective of glial cells","volume":"14","author":"Belov Kirdajova","year":"2020","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0272-0590(87)90029-7","article-title":"Monochloroacetic acid toxicity in the mouse associated with blood-brain barrier damage","volume":"9","author":"Berardi","year":"1987","journal-title":"Fundamental and Applied Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0115","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ejca.2015.06.123","article-title":"Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial","volume":"51","author":"van den Berg","year":"2015","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0120","first-page":"120","article-title":"A prelusive clinical trial of cyclophosphamide","volume":"8","author":"Bergsagel","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0125","first-page":"112","article-title":"Phase II evaluation of cyclophosphamide","volume":"8","author":"Bethell","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pharmthera.2012.05.003","article-title":"The glycine deportation system and its pharmacological consequences","volume":"135","author":"Beyoglu","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685732","article-title":"The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion","volume":"36","author":"Boddy","year":"1995","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0378-4347(92)80514-Q","article-title":"Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma","volume":"575","author":"Boddy","year":"1992","journal-title":"Journal of Chromatography"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0145","first-page":"3758","article-title":"Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children","volume":"53","author":"Boddy","year":"1993","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0150","first-page":"727","article-title":"Experimental bases of cancer chemotherapy; biochemical, pharmacological and histopathological studies with nitrogen mustard N-oxide","volume":"7","author":"Brock","year":"1957","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00524216","article-title":"The form of transport and action as a chemotherapeutic principle in the treatment of tumors","volume":"62","author":"Brock","year":"1957","journal-title":"Zeitschrift f\u00fcr Krebsforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0160","first-page":"1","article-title":"Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents","volume":"8","author":"Brock","year":"1958","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/978-3-642-81488-4_32","article-title":"The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics","volume":"74","author":"Brock","year":"1980","journal-title":"Recent Results in Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0170","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/1097-0142(197106)27:6<1512::AID-CNCR2820270636>3.0.CO;2-Q","article-title":"Activation of cyclophosphamide in man and animals","volume":"27","author":"Brock","year":"1971","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01483611","article-title":"On the problem of bone marrow injury by cancerotoxic substances","volume":"38","author":"Brock","year":"1960","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0180","first-page":"1021","article-title":"on the Activation of Cyclophosphamide in Vivo and in Vitro","volume":"13","author":"Brock","year":"1963","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00410691","article-title":"Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds","volume":"100","author":"Brock","year":"1981","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0190","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0014-2964(81)90261-9","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - I. Experimental studies on the urotoxicity of alkylating compounds","volume":"17","author":"Brock","year":"1981","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0195","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0277-5379(81)80019-3","article-title":"Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds","volume":"17","author":"Brock","year":"1981","journal-title":"European Journal of Cancer & Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF00369371","article-title":"Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide","volume":"66","author":"Brock","year":"1979","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0205","first-page":"659","article-title":"Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide","volume":"29","author":"Brock","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-0028-1114243","article-title":"Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B 518 ASTA","volume":"83","author":"Brock","year":"1958","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-005-0061-0","article-title":"Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite","volume":"57","author":"Bruggemann","year":"2006","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0220","first-page":"4734","article-title":"Quantification by gas chromatography of N,N\u2019-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide","volume":"40","author":"Bryant","year":"1980","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(80)92703-8","article-title":"Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma","volume":"2","author":"Bryant","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0230","first-page":"394","article-title":"The mucolytic effect of Mesna","volume":"23","author":"Burgi","year":"1974","journal-title":"Anaesthesist"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0235","first-page":"760","article-title":"Prevention of urinary tract toxicity of oxazaphosphorines by a \"uroprotector\". Report on a field study (author's transl)","volume":"121","author":"Burkert","year":"1979","journal-title":"MMW, M\u00fcnchener Medizinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0240","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3181\/00379727-143-37450","article-title":"Teratogenicity and neonatal toxicity of ifosfamide in mice","volume":"143","author":"Bus","year":"1973","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0245","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(85)91288-7","article-title":"Ifosfamide\/mesa and encephalopathy","volume":"1","author":"Cantwell","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0250","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/1097-0142(19811001)48:7<1517::AID-CNCR2820480707>3.0.CO;2-8","article-title":"Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP)","volume":"48","author":"Carmo-Pereira","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0255","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/1097-0142(19811101)48:9<1947::AID-CNCR2820480906>3.0.CO;2-M","article-title":"Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF)","volume":"48","author":"Carmo-Pereira","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/oxfordjournals.annonc.a058317","article-title":"The enigma of ifosfamide encephalopathy","volume":"3","author":"Cerny","year":"1992","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0265","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/bjc.1989.265","article-title":"A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC)","volume":"60","author":"Cerny","year":"1989","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0270","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0275","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0022-3565(24)29242-9","article-title":"Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)\/kainate receptors and induce cellular acidification in mouse cortical neurons","volume":"299","author":"Chatton","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0280","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-3565(25)05982-8","article-title":"Studies on the pharmacology of fluoro acetate; species response to fluoroacetate","volume":"87","author":"Chenoweth","year":"1946","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0285","first-page":"169","article-title":"The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round","volume":"84","author":"Christakis","year":"2011","journal-title":"The Yale Journal of Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0290","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/1097-0142(196011\/12)13:6<1254::AID-CNCR2820130614>3.0.CO;2-U","article-title":"Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide)","volume":"13","author":"Coggins","year":"1960","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3565(25)28610-4","article-title":"Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat","volume":"174","author":"Cohen","year":"1970","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0300","first-page":"751","article-title":"Phase I clinical trial of isophosphamide (NSC-109724)","volume":"59","author":"Cohen","year":"1975","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0305","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0006-2952(74)90318-9","article-title":"Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide","volume":"23","author":"Connors","year":"1974","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0310","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/bms.1200010209","article-title":"Observations on the mechanism of hydroxylation of cyclophosphamide by rat liver microsomes: the metabolism of cyclophosphamide-4-d2","volume":"1","author":"Connors","year":"1974","journal-title":"Biomedical Mass Spectrometry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0315","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1200\/JCO.1984.2.11.1260","article-title":"A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer","volume":"2","author":"Creagan","year":"1984","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0320","first-page":"1385","article-title":"A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas","volume":"60","author":"Creagan","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0325","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/hed.2890060307","article-title":"Cyclophosphamide, adriamycin, and 24-hour infusion of cis-diamminedichloroplatinum (II) in the management of patients with advanced head and neck neoplasms","volume":"6","author":"Creagan","year":"1984","journal-title":"Head & Neck Surgery"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt1974161part177","article-title":"Clinical pharmacology of isophosphamide","volume":"16","author":"Creaven","year":"1974","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0335","first-page":"445","article-title":"Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724)","volume":"60","author":"Creaven","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00043426-199502000-00006","article-title":"Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia","volume":"17","author":"Crooks","year":"1995","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0345","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1196\/annals.1320.016","article-title":"L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis","volume":"1033","author":"Cruciani","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105976","article-title":"Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data","volume":"175","author":"Cucchiara","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0355","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.coc.0000158439.02724.5a","article-title":"Evaluating risk factors for the development of ifosfamide encephalopathy","volume":"28","author":"David","year":"2005","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0360","first-page":"115","article-title":"Sodium 2-mercapto ethane sulfonate (MESNA) in respiratory resuscitation","volume":"22","author":"De Temmerman","year":"1971","journal-title":"Acta Anaesthesiologica Belgica"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0365","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/978-3-642-96029-1_34","article-title":"Untersuchungen zur Frage der Aktivierung des N,N-Bis-(beta-chloroathyl) N1.O-propylen-phosphorsaureester-amids (Endoxan)","volume":"68","author":"Diefenthal","year":"1962","journal-title":"Verhandlungen der Deutschen Gesellschaft f\u00fcr Innere Medizin"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0370","doi-asserted-by":"crossref","first-page":"12170","DOI":"10.1073\/pnas.92.26.12170","article-title":"A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5\u2019-d(GAC)","volume":"92","author":"Dong","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0375","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1073\/pnas.91.3.1024","article-title":"All four known cyclic adducts formed in DNA by the vinyl chloride metabolite chloroacetaldehyde are released by a human DNA glycosylase","volume":"91","author":"Dosanjh","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0380","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/BF01471475","article-title":"Specific chemotherapy of carcinoma of the prostate","volume":"30","author":"Druckrey","year":"1952","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0385","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.V1281615","article-title":"Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide","volume":"12","author":"Dubourg","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0390","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s002800050698","article-title":"Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers","volume":"40","author":"Ducharme","year":"1997","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0395","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/fcp.12345","article-title":"Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases","volume":"32","author":"Duflot","year":"2018","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0400","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdm104","article-title":"Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy","volume":"18","author":"Durand","year":"2007","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0405","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/mpo.2950120411","article-title":"Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas","volume":"12","author":"Edmonson","year":"1984","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0410","first-page":"1243","article-title":"Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas","volume":"69","author":"Edmonson","year":"1985","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0415","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0090-8258(83)90082-3","article-title":"A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer","volume":"15","author":"Edwards","year":"1983","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0420","series-title":"The chemistry of heterocycles","article-title":"Three-membered heterocycles","author":"Eicher","year":"2012"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0425","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1093\/emboj\/cdg505","article-title":"Crystal structures of 3-methyladenine DNA glycosylase MagIII and the recognition of alkylated bases","volume":"22","author":"Eichman","year":"2003","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0430","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","article-title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0435","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00311275","article-title":"Mutagenic activity of cyclophosphamide, ifosfamide, and trofosfamide in different genes of escherichia coli and salmonella typhimurium after biotransformation through extracts of rodent liver","volume":"33","author":"Ellenberger","year":"1975","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0440","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00265383","article-title":"Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment","volume":"9","author":"Falkson","year":"1982","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0445","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jamcollsurg.2010.10.018","article-title":"First use of intravenous chemotherapy cancer treatment: rectifying the record","volume":"212","author":"Fenn","year":"2011","journal-title":"Journal of the American College of Surgeons"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0450","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1039\/CT8946500899","article-title":"Oxidation of tartaric acid in the presence of iron","volume":"65","author":"Fenton","year":"1894","journal-title":"Journal of the Chemical Society, Transactions"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0455","article-title":"Pineal germinoma in a young adult: A case report","volume":"5","author":"Fernandez-Rodriguez","year":"2022","journal-title":"Cancer Reports (Hoboken)"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0460","first-page":"102","article-title":"Preliminary report: clinical trials with cyclophosphamide in children with acute leukemia","volume":"8","author":"Fernbach","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0465","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/179893a0","article-title":"Prof. George Gomori","volume":"179","author":"Findlay","year":"1957","journal-title":"Nature"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2023.108366_bb0470","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0305-7372(83)80022-X","article-title":"Ifosfamide (with mesna), vincristine and cis-platinum for carcinoma of the head and neck","volume":"10","author":"Focan","year":"1983","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0475","first-page":"57","article-title":"Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro","volume":"21","author":"Foley","year":"1961","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0480","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-022-04951-3","article-title":"C. elegans as a model for inter-individual variation in metabolism","volume":"607","author":"Fox","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0485","first-page":"39","article-title":"Cyclophosphamide. A preliminary study of a new alkylating agent","volume":"6","author":"Foye","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0490","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1021\/ja01189a073","article-title":"Derivatives of 10-methyl-1,2-benzanthracene related to the nitrogen and sulfur beta-chloroethyl vesicants","volume":"70","author":"Friedman","year":"1948","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0495","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.654931","article-title":"The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain","volume":"13","author":"Gasiorowska","year":"2021","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0500","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1113\/jphysiol.1937.sp003503","article-title":"The secretory response of the posterior pituitary to the need for water conservation","volume":"90","author":"Gilman","year":"1937","journal-title":"The Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0505","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1126\/science.84.2166.24","article-title":"The secretion of an antidiuretic hypophyseal hormone in response to the need for renal water conservation","volume":"84","author":"Gilman","year":"1936","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0510","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.103.2675.409","article-title":"The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides","volume":"103","author":"Gilman","year":"1946","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0515","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3181\/00379727-42-10786","article-title":"Micro technical demonstration of phosphatase in tissue sections","volume":"42","author":"Gomori","year":"1939","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0520","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ajcp\/16.6.347","article-title":"The study of enzymes in tissue sections","volume":"16","author":"Gomori","year":"1946","journal-title":"American Journal of Clinical Pathology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0525","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3181\/00379727-69-16735","article-title":"Histochemical demonstration of sites of phosphamidase activity","volume":"69","author":"Gomori","year":"1948","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0530","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0535","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(86)92227-0","article-title":"Dechloroethylation of ifosfamide and neurotoxicity","volume":"2","author":"Goren","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0540","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.bjc.6600413","article-title":"Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients","volume":"86","author":"Graziano","year":"2002","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0545","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00347875","article-title":"Toxicokinetics of chloroethanol in the rat after single oral administration","volume":"49","author":"Grunow","year":"1982","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0550","first-page":"4391","article-title":"Roles of 2-haloethylene oxides and 2-haloacetaldehydes derived from vinyl bromide and vinyl chloride in irreversible binding to protein and DNA","volume":"41","author":"Guengerich","year":"1981","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0555","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF00491929","article-title":"Severe illness caused by the products of bacterial metabolism in a child with a short gut","volume":"144","author":"Haan","year":"1985","journal-title":"European Journal of Pediatrics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0560","first-page":"39","article-title":"The influence of cyclophoaphamide upon neoplastic diseases in man","volume":"8","author":"Haar","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0565","first-page":"442","article-title":"The influence of various polycyclic hydrocarbons on the growth rate of transplantable tumours","volume":"122","author":"Haddow","year":"1937","journal-title":"Proceedings of the Royal Society of London B"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0570","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/157500a0","article-title":"Influence of carbamic esters (urethanes) on experimental animal tumors","volume":"157","author":"Haddow","year":"1946","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0575","first-page":"5167","article-title":"Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients","volume":"48","author":"Hadidi","year":"1988","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0580","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/00498254.2011.590547","article-title":"Racemates revisited: heterochiral assemblies and the example of DL-thalidomide","volume":"41","author":"Hague","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0585","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/jm50006a005","article-title":"Drug latentiation","volume":"1","author":"Harper","year":"1959","journal-title":"Journal of Medicinal and Pharmaceutical Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0590","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1200\/JCO.2007.11.9099","article-title":"Phase I\/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group","volume":"25","author":"Hartmann","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0595","doi-asserted-by":"crossref","first-page":"61970","DOI":"10.18632\/oncotarget.11486","article-title":"Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma","volume":"7","author":"Hattinger","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0600","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00405909","article-title":"Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma","volume":"100","author":"Heim","year":"1981","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0605","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1021\/ja00713a060","article-title":"Isolation and identification of 4-ketocyclophosphamide, a possible active form of the antitumor agent cyclophosphamide","volume":"92","author":"Hill","year":"1970","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0610","first-page":"1016","article-title":"Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite","volume":"33","author":"Hill","year":"1973","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0615","first-page":"658","article-title":"Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite","volume":"32","author":"Hill","year":"1972","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0620","first-page":"116","article-title":"Cyclophosphamide (cytoxan) in acute leukemia, preliminary report","volume":"8","author":"Hoogstraten","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0625","first-page":"47","article-title":"A preliminary clinical study of cyclophosphamide","volume":"9","author":"Host","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0630","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1078155208093930","article-title":"Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant","volume":"14","author":"Howell","year":"2008","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0635","first-page":"1288","article-title":"Efficacy of ifosfamide combined with liposome doxorubicin on osteosarcoma and its effects on serum IL-10, TNF-alpha, and IFN-gamma in patients with osteosarcoma","volume":"14","author":"Huang","year":"2022","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0640","series-title":"IARC monographs on the evaluation of carcinogenic risks to humans","volume":"Vol. 100A","author":"IARC","year":"2012"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0645","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00253-009-1898-7","article-title":"Biosynthetic pathways for 3-hydroxypropionic acid production","volume":"82","author":"Jiang","year":"2009","journal-title":"Applied Microbiology and Biotechnology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0650","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/978-3-642-81685-7_27","article-title":"Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: interim results of an ongoing clinical trial","volume":"80","author":"Jones","year":"1982","journal-title":"Recent Results in Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0655","doi-asserted-by":"crossref","first-page":"14247","DOI":"10.1074\/jbc.M113.458802","article-title":"Translesion synthesis past acrolein-derived DNA adducts by human mitochondrial DNA polymerase gamma","volume":"288","author":"Kasiviswanathan","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0660","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/bmj.1.3622.1044","article-title":"Carcinogenic substances and their fluorescence spectra","volume":"1","author":"Kennaway","year":"1930","journal-title":"British Medical Journal"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0665","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0378-4347(98)00298-9","article-title":"High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes","volume":"716","author":"Kerbusch","year":"1998","journal-title":"Journal of Chromatography. B, Biomedical Sciences and Applications"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0670","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1592\/phco.30.8.812","article-title":"Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy","volume":"30","author":"Kettle","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0675","first-page":"397","article-title":"p53 mutations in cyclophosphamide-associated bladder cancer","volume":"7","author":"Khan","year":"1998","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0680","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tiv.2009.08.026","article-title":"Targets of chloroacetaldehyde-induced nephrotoxicity","volume":"24","author":"Knouzy","year":"2010","journal-title":"Toxicology In Vitro"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0685","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0040-4039(01)96762-0","article-title":"New reaction of adenine and cytosine derivatives, potentially useful for nucleic acids modification","volume":"22","author":"Kochetkov","year":"1971","journal-title":"Tetrahedron Letters"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0690","first-page":"355","article-title":"Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer","volume":"69","author":"Krook","year":"1985","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0695","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.1919.26110010018009f","article-title":"Role of the blood and the bone marrow in certain forms of gas poisoning","volume":"72","author":"Krumbhaar","year":"1919","journal-title":"Journal of the American Medical Association"},{"issue":"497\u2013508","key":"10.1016\/j.pharmthera.2023.108366_bb0700","first-page":"493","article-title":"The blood and bone marrow in yelloe cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases","volume":"40","author":"Krumbhaar","year":"1919","journal-title":"The Journal of Medical Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0705","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"Kupfer","year":"1996","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0710","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0140-6736(94)91839-2","article-title":"Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue","volume":"343","author":"Kupfer","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0715","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0140-6736(90)91487-U","article-title":"Intramolecular rearrangement of ifosfamide in aqueous solutions","volume":"335","author":"Kupfer","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0720","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/tx00029a007","article-title":"1,N2-ethenodeoxyguanosine: properties and formation in chloroacetaldehyde-treated polynucleotides and DNA","volume":"5","author":"Kusmierek","year":"1992","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0725","first-page":"1347","article-title":"Some effects of cyclophosphamide (cytoxan) on normal mice and mice with L1210 leukemia","volume":"23","author":"Lane","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0730","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/188756a0","article-title":"Development of a leukaemia resistant to cyclophosphamide (\u2019Cytoxan\u2019)","volume":"188","author":"Lane","year":"1960","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0735","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF00686635","article-title":"Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide\/mesna therapy","volume":"35","author":"Lauterburg","year":"1994","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0740","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00280-015-2864-y","article-title":"Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer","volume":"76","author":"Lee","year":"2015","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0745","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxlet.2005.09.002","article-title":"Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy","volume":"161","author":"Lerch","year":"2006","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0750","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bcp.2010.06.002","article-title":"Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics","volume":"80","author":"Li","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0755","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.125.3251.728","article-title":"George Gomori, leading histochemist","volume":"125","author":"Lillie","year":"1957","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0760","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/5.3.203","article-title":"George Gomori; 1904-1957","volume":"5","author":"Lillie","year":"1957","journal-title":"The Journal of Histochemistry and Cytochemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0765","first-page":"753","article-title":"Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma","volume":"49","author":"Lind","year":"1989","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0770","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/0006-2952(89)90419-X","article-title":"The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo","volume":"38","author":"Lind","year":"1989","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0775","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuron.2006.03.026","article-title":"NMDA receptors, glial cells, and clinical medicine","volume":"50","author":"Lipton","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0780","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-22-1785","article-title":"Pegylated liposomal doxorubicin combined with ifosfamide for treating advanced or metastatic soft-tissue sarcoma: A prospective, single-arm phase II study","volume":"28","author":"Liu","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0785","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jfma.2015.07.016","article-title":"Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis","volume":"115","author":"Lo","year":"2016","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0790","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.dnarep.2012.11.009","article-title":"Alkyladenine DNA glycosylase (AAG) localizes to mitochondria and interacts with mitochondrial single-stranded binding protein (mtSSB)","volume":"12","author":"van Loon","year":"2013","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0795","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00498250600659122","article-title":"Enantiomer-enantiomer interaction of ifosfamide in the rat","volume":"36","author":"Lu","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0800","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2019.03.007","article-title":"Fatty acid desaturation gets a NAD(+) reputation","volume":"29","author":"Lutkewitte","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0805","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cbi.2012.11.017","article-title":"Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity","volume":"202","author":"MacAllister","year":"2013","journal-title":"Chemico-Biological Interactions"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0810","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002800050963","article-title":"Increased urinary losses of carnitine during ifosfamide chemotherapy","volume":"44","author":"Marthaler","year":"1999","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0815","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/bmj.2.5216.1837","article-title":"Cyclophosphamide in Hodgkin\u2019s disease and related disorders","volume":"2","author":"Matthias","year":"1960","journal-title":"British Medical Journal"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2023.108366_bb0820","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0305-7372(83)80016-4","article-title":"Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma","volume":"10","author":"Matthiessen","year":"1983","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0825","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1124\/dmd.104.002279","article-title":"Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation","volume":"33","author":"McCune","year":"2005","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0830","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(85)91432-1","article-title":"Encephalopathy associated with ifosphamide\/mesna therapy","volume":"1","author":"Meanwell","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0835","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(86)90099-1","article-title":"Avoiding ifosfamide\/mesna encephalopathy","volume":"2","author":"Meanwell","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0840","first-page":"727","article-title":"Phase II study of ifosfamide in cervical cancer","volume":"70","author":"Meanwell","year":"1986","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0845","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1177\/1078155220971794","article-title":"Incidence of ifosfamide induced encephalopathy in patients receiving concomitant fosaprepitant","volume":"27","author":"Modi","year":"2021","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0850","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1042\/BCJ20170814","article-title":"Propionate enters GABAergic neurons, inhibits GABA transaminase, causes GABA accumulation and lethargy in a model of propionic acidemia","volume":"475","author":"Morland","year":"2018","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0855","first-page":"541","article-title":"Determination of 2 vinylchloride metabolites in urine","volume":"62","author":"Muller","year":"1975","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0860","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0304-3835(79)80057-9","article-title":"Identification of S-(carboxymethyl)-L-cysteine and thiodiglycolic acid, urinary metabolites of 2,2'-bis-(chloroethyl)-ether in the rat","volume":"7","author":"Muller","year":"1979","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0865","first-page":"51","article-title":"A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard","volume":"9","author":"Nissen-Meyer","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0870","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0875","first-page":"437","article-title":"Studies on the metabolism of isophosphamide (NSC-109724) in man","volume":"60","author":"Norpoth","year":"1976","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0880","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1515\/bchm2.1970.351.1.377","article-title":"Hypothetical metabolites of 2-bis(2-chloroethyl)amino-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide)","volume":"351","author":"Norpoth","year":"1970","journal-title":"Hoppe-Seyler\u2019s Zeitschrift f\u00fcr Physiologische Chemie"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0885","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/BF01931863","article-title":"Oxidation of cyclophosphamide by means of KMnO 4","volume":"28","author":"Norpoth","year":"1972","journal-title":"Experientia"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0890","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/BF01614384","article-title":"Side chain oxidation of ifosfamide in man","volume":"53","author":"Norpoth","year":"1975","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0895","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01487599","article-title":"Metabolic pathways of cyclophosphamide","volume":"50","author":"Norpoth","year":"1972","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0900","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/BF01489468","article-title":"Testing of a cyclophosphamide metabolite on Yoshida ascites cells in vitro","volume":"49","author":"Norpoth","year":"1971","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0905","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/978-3-642-85448-4_404","article-title":"Quantitative determination of ifosfamide and an ifosfamide metabolite in the human urine","volume":"78","author":"Norpoth","year":"1972","journal-title":"Verhandlungen der Deutschen Gesellschaft f\u00fcr Innere Medizin"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0910","first-page":"373","article-title":"Repair of etheno DNA adducts by N-glycosylases","author":"Oesch","year":"1986","journal-title":"IARC Scientific Publications"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0915","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jama.1960.63020130004012","article-title":"Comparative clinical evaluation of two alkylating agents: mannitol mustard and cyclophosphamide (cytoxan)","volume":"172","author":"Papac","year":"1960","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0920","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/cbic.201300625","article-title":"Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity","volume":"15","author":"Parajuli","year":"2014","journal-title":"Chembiochem"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0925","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0140-6736(46)91555-3","article-title":"Leukaemia treated with urethane, compared with deep x-ray therapy","volume":"1","author":"Paterson","year":"1946","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0930","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/IGC.0000000000000336","article-title":"Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy","volume":"25","author":"Petric Mise","year":"2015","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0935","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1212\/WNL.47.6.1567","article-title":"Human brain GABA levels rise rapidly after initiation of vigabatrin therapy","volume":"47","author":"Petroff","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0940","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0165-1110(94)90015-9","article-title":"DNA damage and mutagenesis induced by nitrogen mustards","volume":"318","author":"Povirk","year":"1994","journal-title":"Mutation Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0945","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/jcb.25103","article-title":"Base Excision Repair in the Mitochondria","volume":"116","author":"Prakash","year":"2015","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/genes9050250","article-title":"Brain Mitochondria, Aging, and Parkinson's Disease","volume":"9","author":"Rango","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0955","first-page":"477","article-title":"Die biologische \u201cAktivierung\u201d von Endoxan\u00ae","volume":"16","author":"Rauen","year":"1965","journal-title":"Arzneimittel-Forschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0960","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF01770886","article-title":"A volatile alkylating agent in the exhaled air following the administration of Endoxan","volume":"46","author":"Rauen","year":"1968","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0965","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF00636826","article-title":"Direct hydroxylation of endoxan","volume":"54","author":"Rauen","year":"1967","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0970","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1078155210385159","article-title":"Evaluation of methylene blue, thiamine, and\/or albumin in the prevention of ifosfamide-related neurotoxicity","volume":"17","author":"Richards","year":"2011","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0975","first-page":"2945","article-title":"Reduction of ifosfamide toxicity using dose fractionation","volume":"36","author":"Rodriguez","year":"1976","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0980","first-page":"50","article-title":"Ifosfamide in the treatment of bladder cancer","volume":"23","author":"Roth","year":"1996","journal-title":"Seminars in Oncology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0985","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-3565(25)11282-2","article-title":"Toxicity in mice of new secondary nitrogen mustards","volume":"111","author":"Rutenburg","year":"1954","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0990","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0022-3565(24)38783-X","article-title":"Kinetics of monochloroacetic acid in adult male rats after intravenous injection of a subtoxic and a toxic dose","volume":"296","author":"Saghir","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb0995","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/tx0497705","article-title":"Monochloroacetic acid inhibits liver gluconeogenesis by inactivating glyceraldehyde-3-phosphate dehydrogenase","volume":"18","author":"Sakai","year":"2005","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1000","first-page":"127","article-title":"Comparison of the effectiveness of Cyclophosphamide and Cytembena in controlled clinical trial in nephrotic syndrome and chronic glomerulonephritis","volume":"31","author":"Sasinka","year":"1976","journal-title":"Ceskoslovensk\u00e1 Pediatrie"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.31887\/DCNS.2018.20.4\/jmsaudubray","article-title":"An overview of inborn errors of metabolism affecting the brain: From neurodevelopment to neurodegenerative disorders","volume":"20","author":"Saudubray","year":"2018","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1010","first-page":"501","article-title":"Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results","volume":"63","author":"Scheef","year":"1979","journal-title":"Cancer Treatment Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ijc.2910190111","article-title":"A dose-response study on urethane carcinogenesis in rats and mice","volume":"19","author":"Schmahl","year":"1977","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1020","first-page":"1334","article-title":"Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study","volume":"32","author":"Schnitker","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1025","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/1097-0142(194907)2:4<701::AID-CNCR2820020417>3.0.CO;2-K","article-title":"A study of the inhibition of tumor growth in mice and rats with 10-methyl-1,2-benzanthracene and derivatives related to the nitrogen and sulfur beta-chloroethyl vesicants","volume":"2","author":"Seligman","year":"1949","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00000658-194909000-00004","article-title":"Development of new methods for the histochemical demonstration of hydrolytic intracellular enzymes in a program of cancer research","volume":"130","author":"Seligman","year":"1949","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00258120","article-title":"Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial","volume":"14","author":"Sessa","year":"1985","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1040","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.mex.2019.09.017","article-title":"Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry","volume":"6","author":"Shackman","year":"2019","journal-title":"MethodsX"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/00498258309052281","article-title":"2-Chloroacetaldehyde, a metabolite of cyclophosphamide in the rat","volume":"13","author":"Shaw","year":"1983","journal-title":"Xenobiotica"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2023.108366_bb1050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(83)80003-6","article-title":"2-Chloroacetaldehyde: a metabolite of cyclophosphamide in the rat","volume":"10","author":"Shaw","year":"1983","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1055","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00280-019-03949-5","article-title":"Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases","volume":"84","author":"Shimada","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1191\/0748233702th163oa","article-title":"Therapeutic effects of glucose infusion on monochloroacetic acid exposure in rats","volume":"18","author":"Shimizu","year":"2002","journal-title":"Toxicology and Industrial Health"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1065","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5468\/ogs.2018.61.3.352","article-title":"Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer","volume":"61","author":"Shin","year":"2018","journal-title":"Obstetrics & Gynecology Science"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4143\/crt.2011.43.4.260","article-title":"Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases","volume":"43","author":"Shin","year":"2011","journal-title":"Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00254262","article-title":"Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA)","volume":"11","author":"Shipp","year":"1983","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1080","first-page":"106","article-title":"Preliminary studies with cyclophosphamide","volume":"8","author":"Shnider","year":"1960","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0041-008X(71)90194-3","article-title":"Development of cyclophosphamide activation and its implications in perinatal toxicity to mice","volume":"19","author":"Short","year":"1971","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1090","first-page":"989","volume":"59","author":"Sitarz","year":"1975","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1095","first-page":"1","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/II study","author":"Stamatoullas","year":"2022","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1100","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1177\/0269881109105450","article-title":"Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium","volume":"24","author":"Stanford","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/bjc.1993.391","article-title":"Depletion of circulating cyst(e)ine by oral and intravenous mesna","volume":"68","author":"Stofer-Vogel","year":"1993","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1110","first-page":"3069","article-title":"Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice","volume":"33","author":"Stoner","year":"1973","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1115","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ajcp\/28.4.405","article-title":"In memoriam, George Gomori; 1904-1957","volume":"28","author":"Stowell","year":"1957","journal-title":"American Journal of Clinical Pathology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/bjc.1983.2","article-title":"Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide","volume":"47","author":"Struck","year":"1983","journal-title":"British Journal of Cancer"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2023.108366_bb1125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0305-7372(83)80023-1","article-title":"High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma","volume":"10","author":"Stuart-Harris","year":"1983","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00254247","article-title":"High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma","volume":"11","author":"Stuart-Harris","year":"1983","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1135","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00002018-200831110-00003","article-title":"Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature","volume":"31","author":"Sweiss","year":"2008","journal-title":"Drug Safety"},{"issue":"Suppl A","key":"10.1016\/j.pharmthera.2023.108366_bb1140","first-page":"1","article-title":"Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983","volume":"10","author":"Symposium","year":"1983","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1078155214527143","article-title":"An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center","volume":"21","author":"Szabatura","year":"2015","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0005-2728(98)00161-3","article-title":"The mitochondrial genome: structure, transcription, translation and replication","volume":"1410","author":"Taanman","year":"1999","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","article-title":"Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors","volume":"15","author":"Tajino","year":"2010","journal-title":"Journal of Orthopaedic Science"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1160","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1016\/S0021-9258(19)42403-4","article-title":"Structure and methylation of coenzyme M(HSCH2CH2SO3)","volume":"249","author":"Taylor","year":"1974","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/1354750X.2020.1754913","article-title":"Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients","volume":"25","author":"Torres Espindola","year":"2020","journal-title":"Biomarkers"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0009-8981(63)90163-3","article-title":"Determination of alkylating agents in biological fluids. Method using the color reaction with 4-(4-nitrobenzyl)-pyridine in an alkaline medium","volume":"8","author":"Truhaut","year":"1963","journal-title":"Clinica Chimica Acta"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108366_bb1180","first-page":"159","article-title":"A clinical trial of cyclophosphamide (NSC-26271) and radiation therapy for oat cell carcinoma of the lung","volume":"3","author":"Tucker","year":"1973","journal-title":"Cancer Chemotherapy Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12328-009-0131-7","article-title":"Treatment of intraabdominal desmoplastic small round cell tumor with ifosfamide-based chemotherapy","volume":"3","author":"Ujihara","year":"2010","journal-title":"Clinical Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1190","doi-asserted-by":"crossref","DOI":"10.1177\/2324709618786769","article-title":"Ifosfamide-induced metabolic encephalopathy in 2 patients with cutaneous T-cell lymphoma successfully treated with methylene blue","volume":"6","author":"Vakiti","year":"2018","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1195","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide","volume":"32","author":"Van Dyk","year":"1972","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Research. Part C, Embryo Today"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1205","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1039\/JR9570000805","article-title":"Synthesis of new sugar derivatives of potential antitumor activity","volume":"151","author":"Vargha","year":"1957","journal-title":"Journal of the Chemical Society"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1210","first-page":"986","article-title":"Investigation of the activity of cytoxan against leukemia L1210 in mice","volume":"19","author":"Venditti","year":"1959","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-1110(90)90038-D","article-title":"Mutagenicity of ethyleneimine","volume":"238","author":"Verschaeve","year":"1990","journal-title":"Mutation Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1220","first-page":"12","article-title":"Pharmacogenetic profiling in high-risk soft tissue sarcomas treated with neoadjuvant chemotherapy","author":"Virgili Manrique","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1225","first-page":"193","article-title":"Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats","volume":"26","author":"Visarius","year":"1998","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(97)00767-9","article-title":"Stimulation of respiration by methylene blue in rat liver mitochondria","volume":"412","author":"Visarius","year":"1997","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1235","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-3565(24)38206-0","article-title":"Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats","volume":"289","author":"Visarius","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1240","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0006-2952(94)90387-5","article-title":"Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide","volume":"47","author":"Walker","year":"1994","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: A randomized controlled trial","volume":"36","author":"Xiong","year":"2019","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1250","first-page":"521","article-title":"Cerebral gluconeogenesis and diseases","volume":"7","author":"Yip","year":"2016","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1255","first-page":"1985","article-title":"Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children","volume":"3","author":"Yule","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108366_bb1260","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"Glutamate as a neurotransmitter in the healthy brain","volume":"121","author":"Zhou","year":"2014","journal-title":"Journal of Neural Transmission (Vienna)"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582300030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582300030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:29:32Z","timestamp":1759012172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582300030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":252,"alternative-id":["S016372582300030X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108366","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ifosfamide - History, efficacy, toxicity and encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108366"}}